Anti-Neurofascin (IgG + IgA)

Optimal result: 0.1 – 10 Units

Anti-neurofascin autoantibodies are found mainly in combined central and peripheral demyelination (CCPD), a rare demyelinating condition affecting both CNS and peripheral nervous system (PNS) tissues, and also in chronic inflammatory demyelinating polyneuropathy (CIDP) and axonal injury in patients with multiple sclerosis (MS). Recognition of this antibody may be important in treatment management, becauseanti-neurofascin seropositive CCPD patients respond well to Intravenous Immunoglobulin or plasma exchange treatments.

Neurofascin (NF) is a cell adhesion molecule (= cell adhesion molecules are transmembrane glycoproteins that enable cells to bind together and attach to the extracellular matrix).

NF is expressed in both the CNS and the peripheral nervous system (PNS) and plays important roles in developing and maintaining neural structures.

Anti-neurofascin autoantibodies are found mainly in combined central and peripheral demyelination (CCPD), a rare demyelinating condition affecting both CNS and peripheral nervous system (PNS) tissues, and also in chronic inflammatory demyelinating polyneuropathy (CIDP) and axonal injury in patients with multiple sclerosis (MS). Recognition of this antibody may be important in treatment management, becauseanti-neurofascin seropositive CCPD patients respond well to Intravenous Immunoglobulin or plasma exchange treatments.

Neurofascin (NF) is a cell adhesion molecule (= cell adhesion molecules are transmembrane glycoproteins that enable cells to bind together and attach to the extracellular matrix).

NF is expressed in both the CNS and the peripheral nervous system (PNS) and plays important roles in developing and maintaining neural structures.

Anti-neurofascin autoantibodies are found mainly in combined central and peripheral demyelination (CCPD), a rare demyelinating condition affecting both CNS and peripheral nervous system (PNS) tissues, and also in chronic inflammatory demyelinating polyneuropathy (CIDP) and axonal injury in patients with multiple sclerosis (MS). Recognition of this antibody may be important in treatment management, becauseanti-neurofascin seropositive CCPD patients respond well to Intravenous Immunoglobulin or plasma exchange treatments.

References:

Kawamura N. [Anti-neurofascin antibody in combined central and peripheral demyelination]. Nihon Rinsho. 2015 Sep;73 Suppl 7:347-51. Japanese. PMID: 26480724.

Shelly S, Klein CJ, Dyck PJB, Paul P, Mauermann ML, Berini SE, Howe B, Fryer JP, Basal E, Bakri HM, Laughlin RS, McKeon A, Pittock SJ, Mills J, Dubey D. Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes. Neurology. 2021 Dec 14;97(24):e2392-e2403. doi: 10.1212/WNL.0000000000012932. Epub 2021 Oct 11. PMID: 34635556; PMCID: PMC8673722.

Mathey, E. K.; Derfuss, T.; Storch, M. K.; Williams, K. R.; Hales, K.; Woolley, D. R.; Al-Hayani, A.; Davies, S. N.; Rasband, M. N.; Olsson, T.; Moldenhauer, A.; Velhin, S.; Hohlfeld, R.; Meinl, E.; Linington, C., Neurofascin as a novel target for autoantibody-mediated axonal injury. The Journal of Experimental Medicine 2007, 204 (10), 2363-2372.

Kawamura, N.; Yamasaki, R.; Yonekawa, T.; Matsushita, T.; Kusunoki, S.; Nagayama, S.; Fukuda, Y.; Ogata, H.; Matsuse, D.; Murai, H.; Kira, J.-i., Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 2013, 81 (8), 714-722.

Anti-Neurofascin (IgG + IgA)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Anti-Neurofascin (IgG + IgA) — 10,000+ markers explained
One Anti-Neurofascin (IgG + IgA) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro